Literature DB >> 26818644

HIV pharmacotherapy: A review of integrase inhibitors.

Elaine Wong1, Nathan Trustman, April Yalong.   

Abstract

Integrase strand transfer inhibitors (INSTIs) are a class of antiretroviral agents used to treat HIV. These drugs--raltegravir, elvitegravir, and dolutegravir--are preferred options for treatment-naïve patients when used in combination with two nucleoside reverse transcriptase inhibitors. Based on clinical trials, INSTIs have been proven to be effective with minimal safety concerns. This article reviews the pharmacologic profile, role in therapy, and safety and efficacy of each agent.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26818644     DOI: 10.1097/01.JAA.0000475465.07971.19

Source DB:  PubMed          Journal:  JAAPA        ISSN: 0893-7400


  10 in total

Review 1.  Investigational protease inhibitors as antiretroviral therapies.

Authors:  Narasimha M Midde; Benjamin J Patters; Pss Rao; Theodore J Cory; Santosh Kumar
Journal:  Expert Opin Investig Drugs       Date:  2016-08-02       Impact factor: 6.206

Review 2.  The Curtius Rearrangement: Applications in Modern Drug Discovery and Medicinal Chemistry.

Authors:  Arun K Ghosh; Margherita Brindisi; Anindya Sarkar
Journal:  ChemMedChem       Date:  2018-10-11       Impact factor: 3.466

3.  Prevalence of resistance to integrase strand-transfer inhibitors (INSTIs) among untreated HIV-1 infected patients in Morocco.

Authors:  Najwa Alaoui; Moulay Abdelaziz El Alaoui; Nadia Touil; Hicham El Annaz; Marouane Melloul; Reda Tagajdid; Naoufal Hjira; Mohamed Boui; El Mostapha El Fahime; Saad Mrani
Journal:  BMC Res Notes       Date:  2018-06-08

Review 4.  Recent advances in the discovery of small-molecule inhibitors of HIV-1 integrase.

Authors:  Eungi Choi; Jayapal Reddy Mallareddy; Dai Lu; Srikanth Kolluru
Journal:  Future Sci OA       Date:  2018-09-06

5.  Viral suppression in adults, adolescents and children receiving antiretroviral therapy in Cameroon: adolescents at high risk of virological failure in the era of "test and treat".

Authors:  Joseph Fokam; Samuel Martin Sosso; Bouba Yagai; Serge Clotaire Billong; Rina Estelle Djubgang Mbadie; Rachel Kamgaing Simo; Serge Valery Edimo; Alex Durand Nka; Aline Tiga Ayissi; Junie Flore Yimga; Désiré Takou; Sylvie Moudourou; Marinette Ngo Nemb; Jean-Bosco Nfetam Elat; Maria-Mercedes Santoro; Carlo-Federico Perno; Vittorio Colizzi; Alexis Ndjolo
Journal:  AIDS Res Ther       Date:  2019-11-19       Impact factor: 2.250

Review 6.  Benzothiazoles as potential antiviral agents.

Authors:  Yahya I Asiri; Abdulrhman Alsayari; Abdullatif B Muhsinah; Yahia N Mabkhot; Mohd Z Hassan
Journal:  J Pharm Pharmacol       Date:  2020-07-24       Impact factor: 3.765

Review 7.  Host Defence RNases as Antiviral Agents against Enveloped Single Stranded RNA Viruses.

Authors:  Jiarui Li; Ester Boix
Journal:  Virulence       Date:  2021-12       Impact factor: 5.882

8.  [Evolution of nutritional status, immunological and virological parameters in children with vertically transmitted HIV under antiretroviral treatment]

Authors:  María Georgina Oberto; Elizabeth Liliana Asis; María Daniela Defagó
Journal:  Rev Fac Cien Med Univ Nac Cordoba       Date:  2021-12-28

Review 9.  Development of Azaindole-Based Frameworks as Potential Antiviral Agents and Their Future Perspectives.

Authors:  J B Senthil Kumar; Parthasarathi Das; Vibha Tandon
Journal:  J Med Chem       Date:  2022-04-28       Impact factor: 8.039

10.  Cohort profile: The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE).

Authors:  Arturo Ciccullo; Gianmaria Baldin; Amedeo Capetti; Vanni Borghi; Gaetana Sterrantino; Alessandra Latini; Giordano Madeddu; Luigi Celani; Francesca Vignale; Barbara Rossetti; Alex Dusina; Maria Vittoria Cossu; Sibilla Restelli; William Gennari; Filippo Lagi; Andrea Giacomelli; Manuela Colafigli; Lucia Brescini; Alberto Borghetti; Cristina Mussini; Stefano Rusconi; Simona Di Giambenedetto
Journal:  BMJ Open       Date:  2019-12-02       Impact factor: 2.692

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.